Cancer Program

Non-Small Cell Lung Cancer (NSCLC) Program – Intravenous (IV) PB01

NSCLC accounts for >85% of all lung cancers. Globally, 1.5M people are diagnosed with NSCLC annually. Long term outcomes are very poor for patients with advanced disease, with only approximately 5% surviving 5 years.

PB01 in vivo studies have shown that parenterally administered PB01 enhances the sensitivity of resistant NSCLC cells to chemotherapy agents, and also reduces platinum-based nephrotoxicity. PB01’s activity in other cancer cell lines is currently underway.

paranta-oncology